```html

Fifth Disease (Parvovirus B19 Infection)

Overview

Fifth disease, also known as erythema infectiosum or “slapped‑cheek” syndrome, is a mild viral illness most commonly caused by human parvovirus B19. The virus infects red‑blood‑cell precursors in the bone marrow, leading to a short‑lived drop in red blood cell production. While the classic rash is most recognizable in school‑age children, the infection can affect people of any age, including adults and pregnant women.

In the United States, serologic studies suggest that up to 50–60% of children are infected with parvovirus B19 by age 15.<sup>[1] CDC, 2023</sup> Outbreaks tend to occur in late winter and early spring, especially in schools and daycare centers where close contact facilitates spread.

Symptoms

Symptoms develop in three phases and can vary by age and immune status.

Phase 1 – Early (Prodromal) Symptoms (3‑7 days)

• Low‑grade fever (≤38.5 °C / 101 °F)
• Headache
• General malaise and fatigue
• Runny nose or mild upper‑respiratory congestion
• Occasional sore throat

Phase 2 – Rash (Erythema Infectiosum) (5‑14 days)

• “Slapped‑cheek” facial erythema – bright red, sharply demarcated rash on both cheeks.
• Pink or red “lacy” rash on the trunk, arms, and legs; may become more pronounced when the skin is warmed (e.g., after a hot shower).
• Rash can last 1‑3 weeks; in some adults it may be faint or absent.
• Itching is usually mild or absent.

Phase 3 – Late (Arthralgia/Arthritis) (2‑6 weeks)

• Joint pain (arthralgia) – often symmetric and affecting hands, wrists, knees, and ankles.
• Joint swelling or stiffness, especially in women 20‑40 years old.
• Symptoms may linger for months in rare cases (chronic arthropathy).

Other Possible Manifestations

• Transient anemia (especially in patients with underlying hemolytic disorders).
• In immunocompromised individuals: prolonged fever, persistent rash, or aplastic crisis.
• Fetal infection in pregnant women can lead to hydrops fetalis or miscarriage (see Complications).

Causes and Risk Factors

Parvovirus B19 is a small, non‑enveloped DNA virus transmitted primarily by respiratory droplets and close personal contact. The virus is resistant to the acidic environment of the throat, facilitating spread through saliva, nasal secretions, and occasionally via blood products.

Key Risk Factors

• Age: Children 5‑15 years are the most common group.
• Close‑contact settings: Schools, daycare centers, military barracks, and nursing homes.
• Pregnancy: Women in the first half of pregnancy are at higher risk for fetal complications.
• Underlying hematologic disease: Sickle cell disease, thalassemia, or hereditary spherocytosis increase susceptibility to severe anemia.
• Immunosuppression: HIV infection, chemotherapy, organ transplant recipients, or long‑term corticosteroid use can lead to chronic infection.

Diagnosis

Diagnosis is usually clinical, based on the characteristic rash and epidemiologic clues. Laboratory confirmation is recommended when the presentation is atypical, complications are suspected, or pregnancy is involved.

Laboratory Tests

• Serology: Detection of IgM antibodies (appear 1‑2 weeks after infection, persist ~2‑3 months) and IgG antibodies (appear later, confer lifelong immunity).
• Polymerase Chain Reaction (PCR): Detects viral DNA in blood, bone marrow, or tissue; most sensitive during the early viremic phase.
• Complete Blood Count (CBC): May show transient leukopenia, mild thrombocytopenia, or a drop in hemoglobin (especially in patients with hemolytic anemia).
• Reticulocyte count: Decreased reticulocytes indicate bone‑marrow suppression.

Imaging (rarely needed)

• Chest X‑ray if respiratory symptoms are severe.
• Ultrasound for fetal assessment in pregnant women with confirmed infection.

Treatment Options

There is no specific antiviral therapy for parvovirus B19. Management focuses on symptom relief and monitoring for complications.

Supportive Care

• Fever and pain: Acetaminophen or ibuprofen (unless contraindicated).
• Hydration: Encourage fluids, especially if fever is present.
• Rest: Particularly during the prodromal phase.

Targeted Interventions

• Aplastic crisis (severe anemia): Hospital admission, blood transfusion, and close hematology follow‑up.
• Chronic infection in immunocompromised patients: Intravenous immunoglobulin (IVIG) 0.4 g/kg daily for 5 days has been shown to clear viremia in >80% of cases.<sup>[2] Lancet Infect Dis, 2021</sup>
• Arthritis in adults: NSAIDs, short courses of low‑dose prednisone if NSAIDs ineffective, and physiotherapy for joint mobility.
• Pregnancy: Close obstetric monitoring; consider fetal ultrasound every 2‑4 weeks. Treatment is supportive; IVIG may be considered in severe maternal disease.

Living with Fifth Disease (Parvovirus B19 Infection)

Most individuals recover fully within a few weeks, but practical steps can ease the illness and prevent spread.

Daily Management Tips

• Skin care: Keep the rash clean; mild moisturizers can relieve itchiness.
• Pain control: Take NSAIDs with food; avoid aspirin in children due to Reye’s syndrome risk.
• Activity modification: Limit strenuous activity if you have joint pain; gentle range‑of‑motion exercises help prevent stiffness.
• Nutrition: Iron‑rich foods (lean meat, beans, leafy greens) support red‑blood‑cell production, especially if you have anemia.
• Hydration & rest: Aim for 8‑10 glasses of water daily and 7‑9 hours of sleep.
• Work/school: Children are usually contagious for about 7 days after rash onset; inform teachers and keep them home until fever resolves.
• Follow‑up: If you have a hemoglobinopathy, schedule a CBC check 1‑2 weeks after illness to ensure recovery.

Prevention

Because there is no vaccine, prevention relies on hygiene and awareness.

• Hand hygiene: Wash hands with soap and water for ≥20 seconds, especially after coughing, sneezing, or touching shared objects.
• Respiratory etiquette: Cover mouth/nose with a tissue or elbow when coughing/sneezing.
• Disinfect surfaces: Use EPA‑approved cleaners on toys, desks, and shared equipment.
• Avoid close contact: Keep children with fever or rash away from school or daycare until they are no longer contagious.
• Screening in vulnerable populations: Pregnant women with known exposure should inform their obstetrician promptly; immunocompromised patients should minimise exposure to outbreaks.
• Blood safety: Parvovirus B19 is rarely transmitted via transfusion, but screening is performed for high‑risk recipients.

Complications

Most cases are self‑limited, but certain groups may develop serious sequelae.

• Aplastic crisis: Sudden, severe drop in red‑blood‑cell production, especially in patients with sickle cell disease or hereditary spherocytosis. May require transfusion.
• Chronic anemia: Persisting for weeks to months in immunodeficient individuals.
• Hydrops fetalis: Fetal heart failure due to severe anemia; can lead to intrauterine death.
• Persistent arthritis: Rarely, joint symptoms last >6 months, mimicking rheumatoid arthritis.
• Neurologic involvement: Very rare cases of encephalitis, meningitis, or Guillain‑Barré‑like syndrome reported.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Parvovirus B19 (Fifth Disease).” Updated 2023. https://www.cdc.gov/parvovirusb19
2. Heegaard ED, et al. “Intravenous Immunoglobulin for Chronic Parvovirus B19 Infection in Immunocompromised Hosts.” Lancet Infectious Diseases. 2021;21(4):e115‑e122.
3. Mayo Clinic. “Fifth disease (erythema infectiosum).” Accessed June 2024. https://www.mayoclinic.org
4. World Health Organization. “Parvovirus B19 infection – Clinical management.” 2022. https://www.who.int
5. Cleveland Clinic. “Parvovirus B19 (Fifth Disease).” Updated 2023. https://my.clevelandclinic.org

```